Quick comparison
| Mounjaro | Wegovy | |
|---|---|---|
| Active ingredient | tirzepatide | semaglutide |
| Mechanism | GIP / GLP-1 | GLP-1 |
| Administration | once-weekly injection | once-weekly injection or daily tablet |
| EU weight management | authorised for defined patient groups | authorised for defined patient groups |
What drives the choice
A clinician considers medical history, current medicines, contraindications, previous treatment, tolerance, treatment goals and availability. A group average from a clinical trial is not enough to choose a medicine for one person.
Effectiveness evidence
Direct clinical trials comparing tirzepatide and semaglutide in obesity are available. Group-level results cannot guarantee an individual outcome and should be interpreted alongside safety and medical context.
Price and availability
Prices are not harmonised across the EU and may vary by country, pack, dose, supply and reimbursement rules.
Sources and review
Information is based on European regulatory sources. Availability, reimbursement and prescribing rules vary between EU countries.
Sources last checked: 1 September 2026.